Although controversial, purging of the autograft may be necessary to optimize transplant outcome, especially if better treatments become available to eliminate or control residual disease that may be left after the conditioning regimen. The intent of this study was to show that immunological purging with the cytotoxic cell line NK-92 effectively reduces the number of clonogenic cells and that the method can be performed in compliance with GMP. Owing to the easy quantification of bcr-abl transcripts, chronic myelogenous leukemia (CML) was used as a model disease for proof of principle. A detection level of 10 À7 bcr-abl+ cells and purging efficiency of four logs were achievable for the bcr-abl+ cell line, K562. Leukapheresis products collected from CML patients after stem cell mobilization were then tested. For all patients tested, residual CML cells were highly sensitive to purging by NK-92 with a purging efficacy of several logs. No adverse effect on hematopoietic progenitor cell function was noted. These results demonstrate the efficacy of NK-92 as a purging agent to decrease or eliminate malignant contamination of autologous stem cell grafts and establish proof of principle for ex vivo purging of CML autografts using cytotoxic effector cells.
Although controversial, purging of the autograft may be necessary to optimize transplant outcome, especially if better treatments become available to eliminate or control residual disease that may be left after the conditioning regimen. The intent of this study was to show that immunological purging with the cytotoxic cell line NK-92 effectively reduces the number of clonogenic cells and that the method can be performed in compliance with GMP. Owing to the easy quantification of bcr-abl transcripts, chronic myelogenous leukemia (CML) was used as a model disease for proof of principle. A detection level of 10 À7 bcr-abl+ cells and purging efficiency of four logs were achievable for the bcr-abl+ cell line, K562. Leukapheresis products collected from CML patients after stem cell mobilization were then tested. For all patients tested, residual CML cells were highly sensitive to purging by NK-92 with a purging efficacy of several logs. No adverse effect on hematopoietic progenitor cell function was noted. These results demonstrate the efficacy of NK-92 as a purging agent to decrease or eliminate malignant contamination of autologous stem cell grafts and establish proof of principle for ex vivo purging of CML autografts using cytotoxic effector cells. Bone Marrow Transplantation (2003) 31, 1119-1125. doi:10.1038/sj.bmt.1704117 Keywords: autologous stem cell transplantation; ex vivo purge; CML; NK cells Although allogeneic stem cell transplantation remains the only curative approach for chronic myelogenous leukemia (CML), there are obvious restrictions to its applicability pertaining to the age of the patient and donor availability. [1] [2] [3] [4] Several studies have demonstrated the coexistence of normal hematopoietic progenitor cells with their malignant counterparts in the marrow of patients with CML [5] [6] [7] that could be harvested after chemotherapy and stem cell mobilization. 8, 9 These studies formed the basis for clinical trials using autologous stem cell transplantation following high-dose chemotherapy. [8] [9] [10] [11] [12] Although this approach may ultimately not be curative because of the lack of a graftversus-leukemia effect, it may delay transformation of the disease to allow patients to benefit from novel treatments. 13 Two factors can account for relapse after autologous bone marrow transplantation: the persistence of leukemic cells in the body as well as in the autograft. Stem cell transplantation from a twin, in which case disease-free marrow is transplanted, is still associated with a substantial relapse rate, suggesting that even high doses of chemotherapy or radiation used for transplantation do not completely eliminate the malignant clonogenic cell pool in patients with CML.
14 Although malignant cells surviving in the patient certainly account for a number of relapses, gene marking studies have shown that the reinfusion of residual malignant cells in the autograft can contribute to relapse after the transplant. 15, 16 These latter observations provide the rationale for purging, as a way to provide a 'clean' graft. An immunological graft-versus-leukemia effect could then be introduced after transplantation, which is sufficiently effective to control the disease originating from clonogenic cells in the patient. While CML cells are relatively resistant to cytotoxic drugs and radiation, they are usually sensitive to immunotherapy and particularly natural killer (NK) cell-mediated cytotoxicity. [17] [18] [19] NK cells are a cytotoxic effector population that, in contrast to cytotoxic T lymphocytes (CTL), kill target cell without prior sensitization and therefore constitute a primary line of defense against malignancies and viral infection. 20, 21 Although NK cells can be separated from peripheral blood, activated and expanded, the process is cumbersome and expensive. We, therefore, explored the use of an NK cell line (NK-92) to purge residual CML cells from autologous stem cell collections. NK-92 is an interleukin-2 (IL-2)-dependent human NK cell line (CD3À, CD8À, CD56+, CD16À) with the functional and phenotypic characteristics of activated NK cells. 22 It has been shown to have very potent cytotoxic activity against a broad range of tumor target cells including CML even at low effector:target (E:T) ratios. [23] [24] [25] [26] This broad cytotoxicity is because of the lack of most killer cell inhibitory receptors, but maintained expression of activating receptors. 27 Considering the high cytotoxic activity of NK-92, its potential for ex vivo purging of malignant cells was investigated. 24 Based on these observations, an ex vivo purging method was developed using NK-92 to purge malignant bcr-abl+ CD34+ progenitor cells from stem cell autografts of CML patients.
The bcr-abl+ cell line, K562, was used to establish a semiquantitative PCR technique for the detection of bcrabl and to define optimum purging conditions. Leukapheresis products collected from CML patients after stem cell mobilization were then evaluated, with the objective to determine if they could be purged by NK-92. For all patients tested, residual leukemic cells were sensitive to purging by NK-92 cells with an efficacy of purge of several logs. This study establishes proof of principle for ex vivo purging using the cytotoxic NK-92 cell line.
Materials and methods

Patient samples and cell lines
The bcr-abl+ erythroleukemia cell line K562 was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in RPMI 1640+10% FCS. A neomycin-resistant K562 variant (K562-Neo) was generated as previously described 28 and maintained in media containing 0.8 mg/ml G418 (Life TechnologiesGibco-BRL, Grand Island, NY, USA). The human IL-2-dependent NK cell line NK-92, which was derived from a patient with non-Hodgkin's lymphoma, as described previously, 22 was maintained in a medium, 12.5% FCS, 12.5% horse serum (Myelocult, StemCell Technologies Inc., Vancouver, BC, Canada) supplemented with 100 IU/ ml human recombinant IL-2 (Proleukin, Chiron, Emeryville, CA, USA).
Informed consent and IRB approval were obtained to collect a sample of mobilized stem cells from patients who were scheduled to undergo autologous blood stem cell transplant for CML. An aliquot of mobilized stem cells was obtained for the purpose of these studies prior to cryopreservation.
Antibody and reagents
Tissue culture media and reagents were from either StemCell Technologies (Vancouver, BC, Canada) or Mediatech (Herndon, VA, USA). Fluorescein-(FITC)-or phycoerythrin (PE)-conjugated murine antibodies to human CD34 (clone 8G12) and CD56 (clone My31) were purchased from BD Bioscience (San Jose, CA, USA). Magnetic cell separation was performed using a CliniMACS (Milteyni Biotec, Auburn, CA, USA) according to the manufacturer's recommendations.
RT-PCR and primers
Total RNAs were isolated from K562 cells or CML patients samples (leukapheresis product) and the products of these cells after purging with NK-92 cells, using Trizol. A measure of 2.5 mg of RNA was reverse transcribed using an oligo-dT primer (Promega, Madison, WI, USA) and Supercript II reverse transcriptase. cDNA (2.5 mg) was amplified using specific primers for bcr-abl and b-actin (bcr-abl: 5 0 primer 5 0 -CAG GGT GCA CAG CCG CAA CGG CAA, and 3 0 primer 5 0 -GTC CAG CGA GAA GGT TTT CCT TGG A, b-actin: 5 0 primer 5 0 -CGC GAG AAG ATG ACC CAG ATC, and 3 0 primer 5 0 -TTG CTG ATC CAC ATC TGC TGG). Amplification was accomplished using TAQ polymerase. PCR conditions were as follow: 35 cycles with denaturation at 951C for 1 min, annealing at 551C for 1 min and primer extension at 721C for 2 min. To avoid the formation of primer dimers, a 'hot start' PCR was performed (by adding the TAQ polymerase during the first denaturation period at 951C). To test the integrity of the RNA and to normalize for variations in cDNA synthesis, PCR was performed with the housekeeping gene b-actin, and the bands were visualized and quantified by densitometry. All reagents were from Life TechnologiesGibco-BRL (Grand Island, NY, USA) unless otherwise specified.
Southern blotting
PCR products (20 ml) were separated on a 2% agarose gel, transferred overnight onto a nylon membrane (Zeta probe-GT, BioRad, Hercules, CA, USA), UV crosslinked, prehybridized in 10 Â SSC buffer, and then hybridized to bcr-abl and b-actin probes labeled with [ 32 P]dCTP. Blots were washed in SSPE/SDS buffer under increasing stringency conditions at 551C. Filters were exposed to X-ray film (BioMax, Eastman Kodak, Rochester, NY, USA), and autoradiograms were visualized and quantified by densitometry.
Purging of K562 by NK-92 cells
The bcr-abl+ erythroleukemia cell line K562 was used to establish a semiquantitative RT-PCR/Southern blot assay for CML cells, and to determine the optimal purging conditions. K562 cells were mixed with normal PBMCs to obtain percentages of bcr-abl+ cells ranging from 1:0 (100%) to 1:10 7 (10 À7 ), and the sensitivity of the detection was determined. To establish purging conditions, PBMCs with different contamination levels of K562 cells (30, 20 , and 10%) were cocultured with NK-92 cells at various E:T ratios (1:10, 1:5, 1:1, 5:1, 10:1) for 4 or 18 h. After purging, the cells were harvested, RNA extracted and subjected to RT-PCR and Southern blot analysis using bcr-abl-and b-actin-specific probes. The level of bcr-abl signal was determined by RT-PCR on each sample, and the efficiency of the purge was evaluated by comparing the strength of the signal before and after purge to a titration curve established by RT-PCR analysis of samples with known contamination levels of K562. The autoradiogram was scanned and the bcr-abl and b-actin signals were quantified. A small aliquot of each sample (5 Â 10 5 ) was also taken prior to RNA extraction for flow cytometry analysis and cell count for viability.
Purging of CML autografts by NK-92
Patients' leukapheresis products obtained after mobilization were mixed with normal PBMCs to obtain a titration curve. These serially diluted patient samples (100-0.1%) were analyzed for bcr-abl and b-actin as previously described. To evaluate the ability of NK-92 cells to purge CML cells from patients' autograft, the cells were mixed directly with NK-92 at E:T ratios of 1:10, 1:5, 1:1 and 5:1 and incubated for 4 or 18 h in the presence or absence of IL-2. RNA was extracted and subjected to RT-PCR, and Southern blot analysis using bcr-abl-and b-actin-specific probes. The efficacy of the purge was determined by densitometric analysis and comparing the bcr-abl signal pre-and postpurge to the titration curve.
K562 clonogenic assay
Dilutions of neomycin resistant K562 (K562-Neo) cells were adjusted to give rise to approximately 10-100 large colonies per plate. They were plated in 1.1 ml aliquots of methylcellulose containing Iscove media (StemCell Technologies) supplemented with 30% FCS, 10 À4 b-2 mercaptoethanol, and 2 mM glutamine, containing 0.8 mg/ml G418 (Life Technologies-Gibco-BRL) to establish a titration curve. Purged K562 cells were tested the same way and the efficiency of the purge on clonogenic potential of K562 cells was estimated by comparing the number of colonies obtained by plating purged K562 cells to that of a titration curve.
Hematopoietic progenitor cell assay
Purged products were plated in 1.1 ml aliquots of methylcellulose containing Iscove media at densities adjusted to give approximately 10-100 large colonies of erythroid cells (burst-forming units-erythroid BFU-E), granulocytes and macrophages (CFU-GM), and combinations of these (CFU-GEMM). Colonies were counted under an inverted microscope after 2 weeks.
Flow cytometry
Cells were analyzed by direct immunofluorescence with FITC-or PE-conjugated murine antibodies to human CD34 and CD56. For each sample, 5000 events were collected. Live cells (gated on propidium iodide; Sigma, St Louis, MO, USA) were analyzed on a FACSort flow cytometer (Beckton Dickinson, Mountain View, CA, USA) and analyzed using Hewlett Packard Lysis 2, Macintosh Cellquest or Windows WinMDI (v2.8) software.
Results
NK-92 purging of K562 cells
A semiquantitative RT-PCR-based assay for bcr-abl was first established (schema outlined in Figure 1 ). Using this method, a detection level of 10 À7 bcr-abl+ cells (1 K562 in 10 7 PBMCs) could be achieved. After 18 h of coculture with NK-92 cells, at an E:T ratio of 1:5, a 4 logs decrease of bcrabl+ cells could be achieved (Figure 2 ). Furthermore, purging was improved in the presence of IL-2. This was not (10 À7 ), to obtain different levels of contamination and to establish a titration curve (left panel). To assess the purging ability of NK-92 cells, normal PBMCs with 10, 20 and 30% contamination with K562 were mixed with NK-92 cells at different E:T ratios, incubated for either 4 or 18 h (right panel). RNA was extracted and subjected to RT-PCR, and Southern blot analysis using bcr-abl-and b-actin-specific probes. The efficacy of the purge was determined by comparing the bcr-abl signal before and after the purge to the titration curve. a direct effect of IL-2 or mediated through its effect on PBMCs, but rather mediated through NK-92 as simple culturing of target cells (normal PBMCs spiked with K562) with IL-2 did not have any effect (data not shown). To assess whether the purging efficiency observed by RT-PCR accurately reflected the elimination of clonogenic tumor cells, a clonogenic assay was performed on K562 cells before and after the purge by NK-92. Results with both tests were consistent and the same magnitude of purge on K562 for both PCR detection and clonogenic assay was obtained (data not shown).
Purging of leukapheresis samples obtained from patients with CML
Consistent with the observations for K562, leukapheresis products of CML patients, collected after stem cell mobilization, were also effectively purged by NK-92 cells, particularly at higher E:T ratios (5:1) and after coculture for 18 h. In addition, the purge was more effective in the presence of IL-2, and this effect was mediated through NK-92 cells since incubation of the CML leukapheresis product with IL-2 alone, in the absence of NK-92 cells, did not have an effect (Figure 3) . Densitometric analysis and comparison of the purge to the titration curve, showed that at an E:T ratio of 1:1, after 18 h purge with NK-92 cells in the presence of IL-2, more than 95% of bcr-abl+ cells were purged (Figure 4) . For all six patients tested, residual leukemic cells were sensitive to purging by NK-92 cells with a purging efficacy of 2-4 logs. There was some variability between different patients tested, the less effective purge was observed with patient #5 (2 log at 5:1 E:T ratio) and the best for patient #1(2 log at 1:5 E:T ratio). Overall, purging efficiency was about 2 log at E:T ratio of 1:5 or 1:1, and up to 4 log purge was observed at a E:T ratio of 5:1.
Elimination of NK-92 from the purged autograft by CD34 selection
For any clinical application, NK-92 cells would need to be removed from the purged autograft prior to infusion of the purged autograft to the patient. CD34 selection for stem cells was used to remove NK-92 cells. The number of NK cells (CD56+) and progenitor cells (CD34+) was documented in the autgraft pre-and postpurge in the CD34+ and negative fractions. Using a clinical CD34 selection device (CliniMACSt Miltenyi Biotec, Auburn, CA, USA) complete removal of NK-92 cells and high enrichment for CD34+ progenitor cells could be achieved (over 50% CD34+ recovery at almost 100% purity in the CD34+ fraction) (data not shown).
Effect of NK-92 purge on hematopoietic progenitor cells after purge and CD34 selection
In order to determine if the NK-92 purging process affects hematopoietic cell function, the clonogenic capacity of the hematopoietic cells pre-and postpurge was evaluated. Purged cells were plated in methylcellulose and incubated for 12-14 days. The number and type of colonies were No NK-92 18 hr Effector:target ratio Figure 3 Purging of autografts from patients with CML. A patient sample was purged with NK-92 cells at E:T ratio of 1:10 to 5:1, for either 4 or 18 h. As with K562, longer duration of purge, as well as higher E:T ratios were more effective. The effect of the presence of IL-2 during the purge was also tested. The purge was more effective in the presence of IL-2 (500 IU/ml), and this effect was mediated through NK-92 cells since incubation of CML cells with IL-2 alone, in the absence of NK-92 cells, did not have a significant effect. determined using an inverted phase-contrast microscope and these results were compared to the clonogenic cell growth prior to purge. Purging with NK-92 did not have any impact on the function of hematopoietic progenitor cells, which was fully maintained ( Figure 5 ).
Discussion
There is still significant interest in providing a 'clean' purged stem cell transplant to patients, particularly if posttransplant manipulations of the immune system can prevent relapse that originates from malignant cells that survive the conditioning regimen. We show here, using CML as a model, that effective ex vivo purging can be accomplished with cytotoxic cells. While CML cells can become resistant to cytotoxic drugs and radiation, they are usually sensitive to NK-mediated cytotoxicity. 17, 18 Unfortunately, NK function is deficient in CML patients 29, 30 and studies aimed at activating NK cells and restoring their effector functions by in vivo activation have so far been futile. 21 Hence, CML cells and their early progenitors should be considered for a purging approach that is noncrossreactive with radiation or chemotherapy, such as ex vivo targeting by activated NK cells.
The isolation and expansion of primary NK cells are labor intensive and expensive. As an alternative, the use of cytotoxic cell lines as immune effectors has been proposed. We report here that the highly cytotoxic NK cell line, NK-92, can be used to effectively purge stem cell autografts of CML patients. Using bcr-abl rearrangement as a marker, a detection level of minimal residual disease at 10 À7 and purging efficiency of 4 logs were achieved when K562 was used to standardize the experimental setup. The PCR detectable decrease in bcr-abl+ K562 cells after purging with NK-92 was confirmed in a clonogenic assay that showed dramatically reduced proliferation. Importantly, previous studies have shown that NK-92 do not affect normal hematopoietic progenitor cells number and function. [24] [25] [26] Although NK-92 cells were not irradiated for these studies, other work by our group has confirmed identical killing ability and kinetics with irradiated (500 cGy) NK-92 cells. 24, 26 For all six patients tested, residual bcr-abl+ CML cells were detected in the leukapheresis collections. Purging with NK-92 cells resulted in several log (2-4) depletion of bcrabl cells. Given the low frequency of clonogenic progenitor cells in the apheresis product, it is possible that this level of purge reflects mainly mature bcr-abl+ cells, leaving some bcr-abl+ clonogenic cells unaffected. However, it is unclear what this means with respect to the probability of relapse. Our own studies 31 have suggested that a purged stem cell product, which still has a positive PCR signal for Figure 4 Semiquantitative analysis of purging efficacy of autografts from patients with CML. Serially diluted patient samples (100-0.001%) were analyzed for bcr-abl-and b-actin (top panel) as previously described. The sample was also purged with NK-92 cells at 1:1 ratio for either 4 or 18 h, in the presence or absence of IL-2. Densitometric analysis and comparison of the purge to the titration curve showed that after 18 h purge with NK-92 cells in the presence of IL-2 (500 IU/ml), more than 95% of bcr-abl+ cells were purged. Colonies number and type were evaluated using an inverted phase-contrast microscope. These results were compared to clonogenic output cells prior to purge. Clonogenic assays confirmed that the purge did not alter the function of hematopoietic progenitor cells, which was fully maintained.
malignant disease, can result in complete maintained molecular remission after transplant. It is conceivable that those remaining PCR-positive malignant cells are eliminated during the immune recovery of the patient. Recently STI-571 (Gleevect, Novartis), a selective inhibitor of the BCR-ABL tyrosine kinase, inducing apoptosis of bcr-abl+ cells has generated great interest. 32, 33 A large percentage of patients treated with STI-571 will obtain a cytogeneic remission with very few achieving a molecular remission. In addition, some patients will develop resistance to STI-571 34, 35 and may also become candidates for autologous transplant. It remains to be seen if NK-92-based purging in patients who enter a cytogentic remission will be able to obtain a product that has minimal numbers of clonogenic CML progenitors which could rekindle the interest in autologous transplants for CML.
NK-92 cells have been shown in SCID mice to control leukemia and melanoma and prolong survival. 25, 26 The cell line can be expanded under GMP conditions and clinical trials in patients with advanced cancer are currently underway. 36 No side effects have been reported so far up to a dose of 10 9 cells/kg. To further broaden its clinical application, NK-92 cells have been transfected with an IL-2 gene to prolong survival in vivo. 37 Other variants include tranfectants with chimeric single chain Fv constructs recognizing specific tumor antigens for targeted killing. 38 These developments could make NK-92 cells a more targeted product for ex vivo purging, extending its application to other diseases known to have marrow involvement such as lymphoma, myeloma, and breast cancer.
